Chemotherapy has been used to date as a standard treatment for AML (1), and recently the development of novel therapeutic interventions, including the introduction of the BCL2 inhibitor venetoclax, have positively impacted overall response rates in AML, especially among younger patients (2). This evidence concerns the gene BCL2 and acute myeloid leukemia.